Concert Pharmaceuticals Snags Celgene as a Partner for its DCE Platform®
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 5 (Table of Contents)
Published: 16 May-2013
DOI: 10.3833/pdr.v2013.i5.1939 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Concert Pharmaceuticals has formed its second collaboration of 2013 by partnering with Celgene to develop deuterium-modified compounds targeting cancer and inflammation based on its DCE Platform® (deuterated chemical entity)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS